Urogenital infections caused by microbial pathogens are treated by a pharmaceutical composition that treats or prevents a urogenital bacterial infection and that includes 3,3′-diindolylmethane (DIM), or a DIM-related indole, alone or in combination with epigallocatechin-3-gallate (ECGC) and additionally includes one or more antibacterial agents as an option. Such compositions and methods using same are especially useful for treatment or preventing bacterial infections, for example, Ureaplasma urealyticum, Mycoplasma spp, such as M hominis, N. gonorrhea, T. pallidum, Gardnerella spp., and Chlamydia spp., such as Chlamydia trachomatis. Treatment or prevention of any infection may be directed to the vagina, cervix, and/or uterus.
